Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | IRS1 | P35568 | 1/20 | 0.42 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497061 | 0.94 | NPSR1 (0.51) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL17402505 | 0.89 | NPSR1 (0.58) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL31497070 | 0.84 | NPSR1 (0.47) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL19558977 | 0.84 | RECQL (0.56) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL17405128 | 0.83 | NPSR1 (0.49) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL13477788 | 0.82 | GAA (0.44) | ALDH1A1AKT1IRS1GAB1RECQL | |
| SCHEMBL17079289 | 0.81 | POLB (0.46) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL17288767 | 0.81 | ALDH1A1 (0.42) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL17396758 | 0.81 | NPSR1 (0.41) | NPSR1CYP2C9ALDH1A1AKT1IRS1 | |
| SCHEMBL17390393 | 0.81 | AKT1 (0.43) | NPSR1CYP2C9ALDH1A1AKT1IRS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-10-31 | — | — | US | disclosed |
| US-11958849-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-04-20 | — | — | US | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370786-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-28 | — | — | US | disclosed |
| CN-107074805-B | GLS1 inhibitors for the treatment of disease | 德州大学系统董事会 | 2021-02-26 | — | — | CN | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-31 | — | — | US | disclosed |
| US-10766892-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-09-08 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004417-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004404-A2 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016004417-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | WO | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360121-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
| US-20230124815-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
| US-10766892-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
| US-11370786-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLB1 | NPSR1 2582/4885CYP2C9 2860/4885ALDH1A1 766/4885 |
| US-11958849-B2 | GLS1 inhibitors for treating disease | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
| US-20160002204-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
| US-20200407353-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | NPSR1 2383/4885CYP2C9 3264/4885ALDH1A1 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.